Wisp and Visby Medical Launch First FDA-Cleared At-Home PCR STI Test…

Event summary

Wisp partners with Visby Medical to offer FDA-authorized at-home PCR STI test for chlamydia, gonorrhea, and trichomoniasis.
Test delivers lab-quality results in 30 minutes via mobile app, with Wisp providing follow-up telehealth care.
Program initially targets specific patient outreach, with plans to expand nationwide.
Wisp serves 1.8+ million patients as the largest pure-play women’s telehealth provider in the U.S.

The big picture

This partnership aligns with the growing trend of decentralized healthcare, where telehealth providers like Wisp are integrating rapid diagnostic tools to streamline patient care. The collaboration reflects a broader industry shift toward at-home solutions for infectious diseases, reducing barriers to testing and treatment.

What we're watching

Market Expansion: Whether Wisp and Visby can scale the program beyond targeted outreach to broader patient populations.
Regulatory Compliance: How FDA authorization for at-home PCR tests may influence future regulatory frameworks in telehealth diagnostics.
Competitive Dynamics: The pace at which competitors adopt similar integrated testing and care models in women’s health.